Evidence map›Paper›PMID 41509217›Full record

ArticlebioRxiv : the preprint server for biology2025

SNAP: Streamlined Nextflow Analysis Pipeline for Immunoprecipitation-Based Epigenomic Profiling of Circulating Chromatin.

Ze Zhang, Paulo Da Silva Cordeiro, Surya B Chhetri, Brad Fortunato, Zhenjie Jin, Razane El Hajj Chehade, Karl Semaan, Gunsagar Gulati, Garyoung Gary Lee, Christopher Hemauer and 16 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ze ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9854-5823
Paulo Da Silva CordeiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3750-5582
Surya B ChhetriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brad FortunatoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zhenjie JinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0009-2609-8206
Razane El Hajj ChehadeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0007-3424-6585
Karl SemaanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0004-2315-8422
Gunsagar GulatiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2798-6220
Garyoung Gary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7084-1663
Christopher HemauerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0009-3790-1500
Weiwei BianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1536-2947
Shahabeddin SotudianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-5864-6192
Ziwei ZhangHarvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-0246-6619
David Osei-HwediehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7695-9643
Tanya E HeimMusculoskeletal Oncology Tumor Registry, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Corrie PainterPrecede Biosciences, Boston, MA.
Rashad NawfalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-5428-5660
Marc EidDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4738-5695
Damien VasseurDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-8787-1498
John CanniffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0003-2954-4730
Hunter SavignanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0007-9138-9363
Noa PhillipsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0004-7232-2364
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7280-3334
Kurt R WeissMusculoskeletal Oncology Tumor Registry, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4087-8606

Funding

Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discoveryU01CA296432 · NCI · DANA-FARBER CANCER INST · PI Sylvan C. Baca · 2025 to 2026
$1.4M
NCI NIH HHS U01 CA296432
6 · The paper itself

Abstract

Epigenomic profiling of circulating chromatin is a powerful and minimally invasive approach for detecting and monitoring disease, but there are no bioinformatics pipelines tailored to the unique characteristics of cell-free chromatin. We present SNAP (Streamlined Nextflow Analysis Pipeline), a reproducible, scalable, and modular workflow specifically designed for immunoprecipitation-based methods for profiling cell-free chromatin. SNAP incorporates quality control metrics optimized for circulating chromatin, including enrichment score and fragment count thresholds, as well as direct estimation of circulating tumor DNA (ctDNA) content from fragment length distributions. It also includes SNP fingerprinting to enable sample identity verification. When applied to cfChIP-seq and cfMeDIP-seq data across multiple cancer types, SNAP's quality filters significantly improved classification performance while maintaining high data retention. Independent validation using plasma from patients with osteosarcoma confirmed the detection of tumor-associated epigenomic signatures that correlated with ctDNA levels and reflected disease biology. SNAP's modular architecture enables straightforward extension to additional cell-free immunoprecipitation-based assays, providing a robust framework to support studies of circulating chromatin broadly. SNAP is compatible with cloud and high-performance computing environments and is publicly available at https://github.com/prc992/SNAP/.

Identifiers

PMID41509217
PMCPMC12776326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.